SYRS vs. INCR, RENB, IMAB, SKYE, SGMT, CYBN, RAPT, CTMX, CRVO, and RGLS
Should you be buying Syros Pharmaceuticals stock or one of its competitors? The main competitors of Syros Pharmaceuticals include InterCure (INCR), Renovaro (RENB), I-Mab (IMAB), Skye Bioscience (SKYE), Sagimet Biosciences (SGMT), Cybin (CYBN), RAPT Therapeutics (RAPT), CytomX Therapeutics (CTMX), CervoMed (CRVO), and Regulus Therapeutics (RGLS). These companies are all part of the "pharmaceutical preparations" industry.
InterCure (NASDAQ:INCR) and Syros Pharmaceuticals (NASDAQ:SYRS) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their media sentiment, dividends, community ranking, earnings, analyst recommendations, profitability, institutional ownership, valuation and risk.
Syros Pharmaceuticals received 358 more outperform votes than InterCure when rated by MarketBeat users. However, 100.00% of users gave InterCure an outperform vote while only 63.89% of users gave Syros Pharmaceuticals an outperform vote.
Syros Pharmaceuticals has a consensus target price of $14.00, indicating a potential upside of 156.88%. Given InterCure's higher possible upside, analysts plainly believe Syros Pharmaceuticals is more favorable than InterCure.
InterCure has higher revenue and earnings than Syros Pharmaceuticals. Syros Pharmaceuticals is trading at a lower price-to-earnings ratio than InterCure, indicating that it is currently the more affordable of the two stocks.
InterCure has a net margin of 0.00% compared to InterCure's net margin of -1,656.34%. Syros Pharmaceuticals' return on equity of 0.00% beat InterCure's return on equity.
InterCure has a beta of 1.63, indicating that its share price is 63% more volatile than the S&P 500. Comparatively, Syros Pharmaceuticals has a beta of 1.75, indicating that its share price is 75% more volatile than the S&P 500.
8.3% of InterCure shares are held by institutional investors. Comparatively, 91.5% of Syros Pharmaceuticals shares are held by institutional investors. 0.2% of InterCure shares are held by insiders. Comparatively, 12.3% of Syros Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.
In the previous week, Syros Pharmaceuticals had 26 more articles in the media than InterCure. MarketBeat recorded 27 mentions for Syros Pharmaceuticals and 1 mentions for InterCure. Syros Pharmaceuticals' average media sentiment score of 0.59 beat InterCure's score of 0.44 indicating that InterCure is being referred to more favorably in the media.
Summary
InterCure beats Syros Pharmaceuticals on 9 of the 17 factors compared between the two stocks.
Get Syros Pharmaceuticals News Delivered to You Automatically
Sign up to receive the latest news and ratings for SYRS and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding SYRS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Syros Pharmaceuticals Competitors List
Related Companies and Tools
